|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | AstraZeneca |
|---|---|
| Information provided by: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00658255 |
Purpose
The purpose of this study is to compare the therapeutic effects of formoterol in Symbicort with formoterol in Oxis Turbuhaler for the treatment of adults with stable asthma.
| Condition | Intervention | Phase |
|---|---|---|
|
Stable Asthma |
Drug: budesonide/formoterol Drug: formoterol |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Crossover Assignment, Safety Study |
| Official Title: | A Randomized, Multicenter, Open-Label, Active-Controlled, Single-Dose, 5-Period, Incomplete Block, Cross-Over Study to Evaluate the Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort pMDI or Oxis Turbuhaler to Adults With Stable Asthma |
| Estimated Enrollment: | 175 |
| Study Start Date: | October 2002 |
| Study Completion Date: | May 2003 |
| Arms | Assigned Interventions |
|---|---|
| 1: Experimental | Drug: budesonide/formoterol |
| 2: Active Comparator | Drug: formoterol |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | SD-039-0729, D5896C00729 |
| Study First Received: | April 1, 2008 |
| Last Updated: | March 27, 2009 |
| ClinicalTrials.gov Identifier: | NCT00658255 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
stable asthma adults formoterol |
Symbicort Oxis Turbuhaler bronchodilation |
|
Anti-Inflammatory Agents Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Symbicort Bronchial Diseases Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Hormones Adrenergic Agonists Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Therapeutic Uses |
Formoterol Immune System Diseases Adrenergic beta-Agonists Budesonide Asthma Anti-Asthmatic Agents Glucocorticoids Pharmacologic Actions Autonomic Agents Lung Diseases Hypersensitivity, Immediate Peripheral Nervous System Agents Bronchodilator Agents Respiratory Hypersensitivity |